2017
Association of Panic Disorder, Generalized Anxiety Disorder, and Benzodiazepine Treatment During Pregnancy With Risk of Adverse Birth Outcomes
Yonkers KA, Gilstad-Hayden K, Forray A, Lipkind HS. Association of Panic Disorder, Generalized Anxiety Disorder, and Benzodiazepine Treatment During Pregnancy With Risk of Adverse Birth Outcomes. JAMA Psychiatry 2017, 74: 1145-1152. PMID: 28903165, PMCID: PMC5710298, DOI: 10.1001/jamapsychiatry.2017.2733.Peer-Reviewed Original ResearchConceptsSerotonin reuptake inhibitor useAdverse birth outcomesLow birth weightSerotonin reuptake inhibitorsWeeks of pregnancyHypertensive diseaseDuration of gestationRespiratory interventionsVentilatory supportCesarean deliveryReuptake inhibitorsPanic disorderPregnancy outcomesInhibitor usePreterm birthBirth outcomesBenzodiazepine treatmentBirth weightAnxiety disordersWorld Mental Health Composite International Diagnostic InterviewPrevious adverse birth outcomesComposite International Diagnostic InterviewAdverse pregnancy complicationsMaternal panic disorderNeonatal pregnancy outcomes
2015
Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial
Yonkers KA, Kornstein SG, Gueorguieva R, Merry B, Van Steenburgh K, Altemus M. Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2015, 72: 1037-1044. PMID: 26351969, PMCID: PMC4811029, DOI: 10.1001/jamapsychiatry.2015.1472.Peer-Reviewed Original ResearchMeSH KeywordsAdultAngerDepressionDouble-Blind MethodFemaleHumansIrritable MoodLuteal PhasePremenstrual Dysphoric DisorderSelective Serotonin Reuptake InhibitorsSertralineTime FactorsTreatment OutcomeConceptsPremenstrual dysphoric disorderSymptom-onset dosingSerotonin reuptake inhibitorsDays of mensesSSRI withdrawalSymptom onsetSymptomatic daysMenstrual cycleClinical trialsDysphoric disorderOutcome measuresScale scoreSRI treatmentTreatment of PMDDClinical Global Impression ScaleAbrupt treatment cessationDepressive Symptomatology-ClinicianTotal DRSP scoresSecondary outcome measuresPrimary outcome measureGlobal Impression ScaleIDS-C scoresUniversity Medical CenterSertraline hydrochlorideBeginning of menses
2014
Pregnant Women With Posttraumatic Stress Disorder and Risk of Preterm Birth
Yonkers KA, Smith MV, Forray A, Epperson CN, Costello D, Lin H, Belanger K. Pregnant Women With Posttraumatic Stress Disorder and Risk of Preterm Birth. JAMA Psychiatry 2014, 71: 897-904. PMID: 24920287, PMCID: PMC4134929, DOI: 10.1001/jamapsychiatry.2014.558.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive AgentsBenzodiazepinesComorbidityConnecticutDepressive Disorder, MajorFemaleHumansMassachusettsPregnancyPregnancy ComplicationsPremature BirthRisk AssessmentSelective Serotonin Reuptake InhibitorsStress Disorders, Post-TraumaticConceptsMajor depressive episodePosttraumatic stress disorderPreterm birthWeeks of pregnancyPregnant womenDepressive episodeModified PTSD Symptom ScalePTSD Symptom ScaleStress disorderBenzodiazepine medicationLikely diagnosisSymptom ScaleComposite International Diagnostic InterviewProspective cohort studySerotonin reuptake inhibitorsLogistic regression analysisCohort studyMedication useReuptake inhibitorsBenzodiazepine treatmentBenzodiazepine usePsychotropic treatmentObstetrical practicePsychiatric illnessAnxiolytic treatment
2012
Depression and Serotonin Reuptake Inhibitor Treatment as Risk Factors for Preterm Birth
Yonkers KA, Norwitz ER, Smith MV, Lockwood CJ, Gotman N, Luchansky E, Lin H, Belanger K. Depression and Serotonin Reuptake Inhibitor Treatment as Risk Factors for Preterm Birth. Epidemiology 2012, 23: 677-685. PMID: 22627901, PMCID: PMC3415566, DOI: 10.1097/ede.0b013e31825838e9.Peer-Reviewed Original ResearchConceptsSerotonin reuptake inhibitorsMajor depressive episodePreterm birthDepressive episodeLogistic regressionSRI useUse of SRIsSerotonin reuptake inhibitor treatmentReuptake inhibitor treatmentEarly preterm birthLate preterm birthProspective cohort studyPreterm birth riskMajor depressive disorderNominal logistic regressionBinary logistic regressionAntidepressant treatmentCohort studyHospital chartsReuptake inhibitorsSymptomatic womenBirth outcomesPregnant womenRisk factorsDepressive disorder
2008
Premenstrual syndrome
Yonkers KA, O'Brien P, Eriksson E. Premenstrual syndrome. The Lancet 2008, 371: 1200-1210. PMID: 18395582, PMCID: PMC3118460, DOI: 10.1016/s0140-6736(08)60527-9.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultContraceptives, Oral, HormonalFemaleHumansMood DisordersPanic DisorderPremenstrual SyndromeSelective Serotonin Reuptake InhibitorsConceptsSevere premenstrual syndromePremenstrual dysphoric disorderPremenstrual syndromeSerotonin reuptake inhibitorsGonadal hormone levelsGonadotropin-releasing hormoneOral contraceptivesReuptake inhibitorsBreast tendernessSerotonergic synapsesReproductive ageHormone levelsDysphoric disorderLuteal phaseOvary axisMost womenOvarian cyclicityBehavioral symptomsDepressed moodSymptomsMood swingsSomatic complaintsPhysical discomfortWomenDaily activities
2005
Pretreatment pattern of symptom expression in premenstrual dysphoric disorder
Pearlstein T, Yonkers KA, Fayyad R, Gillespie JA. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. Journal Of Affective Disorders 2005, 85: 275-282. PMID: 15780697, DOI: 10.1016/j.jad.2004.10.004.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderPMDD symptomsMenstrual cycleDysphoric disorderPatient variabilityIntermittent dosing strategyOnset of menstruationDSM-IV criteriaPatients' durationAnxiety/tensionSertraline treatmentDRSP scoresPatient daysDosing strategiesSevere symptomsDay 2SymptomsTreatment studiesPretreatment patternAnger/irritabilityMood swingsMore daysWomenSymptom expressionTreatment implications
2003
Premenstrual disorders: bridging research and clinical reality
Yonkers KA, Pearlstein T, Rosenheck RA. Premenstrual disorders: bridging research and clinical reality. Archives Of Women's Mental Health 2003, 6: 287-292. PMID: 14628181, DOI: 10.1007/s00737-003-0026-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultConnecticutDepressive DisorderDiagnostic and Statistical Manual of Mental DisordersFemaleHumansPatient Acceptance of Health CarePatient SelectionPremenstrual SyndromePsychiatric Status Rating ScalesSelective Serotonin Reuptake InhibitorsSelf-AssessmentSeverity of Illness IndexSurveys and QuestionnairesTreatment OutcomeConceptsPremenstrual dysphoric disorderPremenstrual symptomsTreatment resultsBrief Patient Health QuestionnaireConcurrent psychiatric conditionsOb-gyn settingsStatistical Manual IV criteriaSerotonin reuptake inhibitorsUsual care settingsPatient Health QuestionnaireMinor depressive disorderActual clinical practiceTypes of symptomsEligible womenPatient characteristicsReuptake inhibitorsOpen trialSymptomatic subgroupCurrent comorbidityIV criteriaClinical trialsDepressive disorderHealth QuestionnaireTypical patientDysphoric disorder
2001
Venlafaxine in the treatment of premenstrual dysphoric disorder.
Freeman E, Rickels K, Yonkers K, Kunz N, McPherson M, Upton G. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstetrics And Gynecology 2001, 98: 737-44. PMID: 11704162, DOI: 10.1016/s0029-7844(01)01530-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultCyclohexanolsDouble-Blind MethodFemaleHumansPremenstrual SyndromePsychiatric Status Rating ScalesSelective Serotonin Reuptake InhibitorsVenlafaxine HydrochlorideConceptsPremenstrual dysphoric disorderDaily symptom reportsTreatment of premenstrual dysphoric disorderDysphoric disorderHamilton Rating Scale for DepressionPremenstrual dysphoric disorder treatmentDSR scoresEfficacy of long-term maintenance treatmentSafety of venlafaxineFlexible-dose trialNew-generation antidepressantsLong-term maintenance treatmentDouble-blind treatmentTreatment cyclesPremenstrual symptom scoresVenlafaxine doseVenlafaxine treatmentSymptom reductionSymptom remissionInhibit serotoninNorepinephrine reuptakePMDD symptomsVenlafaxineSymptom reportingCyclic disorder